{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:28Z","timestamp":1787028568869,"version":"build-2736575974"},"reference-count":281,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian research and innovation agency ARIS","doi-asserted-by":"publisher","award":["P3-0298"],"award-info":[{"award-number":["P3-0298"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian research and innovation agency ARIS","doi-asserted-by":"publisher","award":["J3-4527"],"award-info":[{"award-number":["J3-4527"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian research and innovation agency ARIS","doi-asserted-by":"publisher","award":["20230079"],"award-info":[{"award-number":["20230079"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian research and innovation agency ARIS","doi-asserted-by":"publisher","award":["20250236"],"award-info":[{"award-number":["20250236"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Medical Centre Ljubljana","award":["P3-0298"],"award-info":[{"award-number":["P3-0298"]}]},{"name":"University Medical Centre Ljubljana","award":["J3-4527"],"award-info":[{"award-number":["J3-4527"]}]},{"name":"University Medical Centre Ljubljana","award":["20230079"],"award-info":[{"award-number":["20230079"]}]},{"name":"University Medical Centre Ljubljana","award":["20250236"],"award-info":[{"award-number":["20250236"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteoporosis and sarcopenia are two aspects of the geriatric syndrome that frequently occur together and affect one another in a condition referred to as osteosarcopenia. Preventive and treatment options for osteosarcopenia exist but are mainly focused on the treatment of osteoporosis, as there is still no FDA-approved treatment for sarcopenia. Drugs for osteoporosis include antiresorptive and anabolic drugs and hormonal replacement therapies and are prescribed based on age, BMD and other patient characteristics, which, however, do not include the possible co-existence of sarcopenia. As several studies and clinical trials have shown that the pharmacological treatment of osteoporosis can also affect muscle tissue, in either a positive or negative manner, sarcopenia should be another factor affecting the choice of treatment, especially when facing equal treatment options for osteoporosis. The aim of this review was to summarize our current knowledge on the effects of FDA-approved drugs for the treatment of osteoporosis on muscle quality, mass and function. A better understanding of the effects that certain drugs have on muscle tissue might in the future help us to simultaneously at least partially also address the wasting of muscle tissue and avoid further pharmacologically induced decline.<\/jats:p>","DOI":"10.3390\/ijms26146924","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:33:27Z","timestamp":1752845607000},"page":"6924","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?"],"prefix":"10.3390","volume":"26","author":[{"given":"Zoran","family":"Gavrilov","sequence":"first","affiliation":[{"name":"Lab for Retinal Gene Therapy, Department Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, 8952 Schlieren, Switzerland"},{"name":"Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Lojk","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Clinical Institute for Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Njego\u0161eva cesta 4, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jocd.2009.06.004","article-title":"Beyond FRAX\u00ae: It\u2019s Time to Consider \u201cSarco-Osteopenia\u201d","volume":"12","author":"Binkley","year":"2009","journal-title":"J. Clin. Densitom."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/jcsm.12567","article-title":"Osteosarcopenia: Epidemiology, diagnosis, and treatment\u2014Facts and numbers","volume":"11","author":"Kirk","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Huang, T., Li, C., Chen, F., Xie, D., Yang, C., Chen, Y., Wang, J., Li, J., and Zheng, F. (2023). Prevalence and risk factors of osteosarcopenia: A systematic review and meta-analysis. BMC Geriatr., 23.","DOI":"10.1186\/s12877-023-04085-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Inoue, T., Maeda, K., Nagano, A., Shimizu, A., Ueshima, J., Murotani, K., Sato, K., Hotta, K., Morishita, S., and Tsubaki, A. (2021). Related Factors and Clinical Outcomes of Osteosarcopenia: A Narrative Review. Nutrients, 13.","DOI":"10.3390\/nu13020291"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Greco, E.A., Pietschmann, P., and Migliaccio, S. (2019). Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00255"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/jgs.15716","article-title":"Osteoporosis in Older Persons: Old and New Players","volume":"67","author":"Zanker","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jcsm.12147","article-title":"Welcome to the ICD-10 code for sarcopenia","volume":"7","author":"Anker","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jcsm.12268","article-title":"Pitfalls in the measurement of muscle mass: A need for a reference standard","volume":"9","author":"Buckinx","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2046-2395-3-9","article-title":"It is not just muscle mass: A review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life","volume":"3","author":"McGregor","year":"2014","journal-title":"Longev. Heal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40520-016-0708-1","article-title":"Biomarkers for physical frailty and sarcopenia","volume":"29","author":"Calvani","year":"2017","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.11005\/jbm.2014.21.1.29","article-title":"Interaction between Muscle and Bone","volume":"21","author":"Kaji","year":"2014","journal-title":"J. Bone Metab."},{"key":"ref_14","unstructured":"Duque, G., and Troen, B.R. (2022). Genetics of osteosarcopenia. Osteosarcopenia, Elsevier. Chapter 13."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11914-020-00599-y","article-title":"Muscle, Bone, and Fat Crosstalk: The Biological Role of Myokines, Osteokines, and Adipokines","volume":"18","author":"Kirk","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nm.3917","article-title":"Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice","volume":"21","author":"Dankbar","year":"2015","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11021","DOI":"10.1074\/jbc.M116.770941","article-title":"Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: A novel mechanism in muscle-bone communication","volume":"292","author":"Qin","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4248\/BR201302007","article-title":"IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass","volume":"1","author":"Crane","year":"2013","journal-title":"Bone Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41232-017-0043-8","article-title":"Role of fibroblast growth factors in bone regeneration","volume":"37","author":"Charoenlarp","year":"2017","journal-title":"Inflamm. Regen."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liu, L., Guo, J., Chen, X., Tong, X., Xu, J., and Zou, J. (2021). The Role of Irisin in Exercise-Mediated Bone Health. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.668759"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lu, W., Xiao, W., Xie, W., Fu, X., Pan, L., Jin, H., Yu, Y., Zhang, Y., and Li, Y. (2021). The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.735374"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/jcp.55.9.693","article-title":"Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis","volume":"55","author":"Verma","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/jbmr.1950","article-title":"Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures","volume":"28","author":"Patsch","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hamrick, M.W., McGee-Lawrence, M.E., and Frechette, D.M. (2016). Fatty Infiltration of Skeletal Muscle: Mechanisms and Comparisons with Bone Marrow Adiposity. Front. Endocrinol., 7.","DOI":"10.3389\/fendo.2016.00069"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R561","DOI":"10.1152\/ajpregu.00198.2015","article-title":"Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity","volume":"310","author":"Rivas","year":"2016","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S8756-3282(00)00317-3","article-title":"Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?","volume":"27","author":"Nuttall","year":"2000","journal-title":"Bone"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bone.2019.06.016","article-title":"Mechanisms of palmitate-induced lipotoxicity in osteocytes","volume":"127","author":"Bermeo","year":"2019","journal-title":"Bone"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s13539-014-0146-x","article-title":"Osteosarcopenic obesity: The role of bone, muscle, and fat on health","volume":"5","author":"Ormsbee","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cmet.2017.07.019","article-title":"Regulation of Stem Cell Aging by Metabolism and Epigenetics","volume":"26","author":"Ren","year":"2017","journal-title":"Cell Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.nutos.2024.03.014","article-title":"Inflammatory biomarkers of osteosarcopenia in community-dwelling older woman","volume":"55","author":"Teixeira","year":"2024","journal-title":"Clin. Nutr. Open Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopha.2018.03.080","article-title":"TNF-\u03b1 contributes to postmenopausal osteoporosis by synergistically promoting RANKL-induced osteoclast formation","volume":"102","author":"Zha","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"111203","DOI":"10.1016\/j.injury.2023.111203","article-title":"Cytokines: The links between bone and the immune system","volume":"55","author":"Cai","year":"2024","journal-title":"Injury"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111595","DOI":"10.1016\/j.mad.2021.111595","article-title":"Skeletal Muscle Aging, Cellular Senescence, and Senotherapeutics: Current Knowledge and Future Directions","volume":"200","author":"Englund","year":"2021","journal-title":"Mech. Ageing Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society. Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12603-018-1139-9","article-title":"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management","volume":"22","author":"Dent","year":"2018","journal-title":"J. Nutr. Health Aging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/M22-1034","article-title":"Clinical Guidelines Committee of the American College of Physicians Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.bone.2009.11.026","article-title":"Developing bones are differentially affected by compromised skeletal muscle formation","volume":"46","author":"Nowlan","year":"2010","journal-title":"Bone"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41413-022-00190-4","article-title":"Mechanical regulation of bone remodeling","volume":"10","author":"Wang","year":"2022","journal-title":"Bone Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/febs.15820","article-title":"Cellular and molecular pathways controlling muscle size in response to exercise","volume":"289","author":"Attwaters","year":"2022","journal-title":"FEBS J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00198-017-4151-8","article-title":"Osteosarcopenia: Where bone, muscle, and fat collide","volume":"28","author":"Hirschfeld","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.imr.2016.05.003","article-title":"Function of specialized regulatory proteins and signaling pathways in exercise-induced muscle mitochondrial biogenesis","volume":"5","author":"Erlich","year":"2016","journal-title":"Integr. Med. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40520-021-02073-w","article-title":"Impact of exercise training on muscle mitochondria modifications in older adults: A systematic review of randomized controlled trials","volume":"34","author":"Lippi","year":"2022","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/gerona\/glq109","article-title":"Molecular Adaptations to Aerobic Exercise Training in Skeletal Muscle of Older Women","volume":"65A","author":"Konopka","year":"2010","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1152\/japplphysiol.00786.2012","article-title":"Aerobic exercise training induces skeletal muscle hypertrophy and age-dependent adaptations in myofiber function in young and older men","volume":"113","author":"Harber","year":"2012","journal-title":"J. Appl. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40520-017-0863-z","article-title":"Benefits of resistance training in physically frail elderly: A systematic review","volume":"30","author":"Lopez","year":"2018","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rodrigues, F., Domingos, C., Monteiro, D., and Morou\u00e7o, P. (2022). A Review on Aging, Sarcopenia, Falls, and Resistance Training in Community-Dwelling Older Adults. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19020874"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Talar, K., Hern\u00e1ndez-Belmonte, A., Vetrovsky, T., Steffl, M., Ka\u0142amacka, E., and Courel-Ib\u00e1\u00f1ez, J. (2021). Benefits of Resistance Training in Early and Late Stages of Frailty and Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081630"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Micha\u00eblsson, K., Olofsson, H., Jensevik, K., Larsson, S., Mallmin, H., Berglund, L., Vessby, B., and Melhus, H. (2007). Leisure Physical Activity and the Risk of Fracture in Men. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040199"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1914084","DOI":"10.1001\/jamanetworkopen.2019.14084","article-title":"Association of Physical Activity and Fracture Risk Among Postmenopausal Women","volume":"2","author":"LaMonte","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1519\/JSC.0000000000002209","article-title":"Resistance Training Is Associated with Higher Lumbar Spine and Hip Bone Mineral Density in Competitive Male Cyclists","volume":"32","author":"Mathis","year":"2018","journal-title":"J. Strength Cond. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1519\/JSC.0b013e3181c6a116","article-title":"Longitudinal changes in bone mineral density in male master cyclists and nonathletes","volume":"25","author":"Nichols","year":"2011","journal-title":"J. Strength Cond. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-155-10-201111150-00006","article-title":"Whole-body vibration therapy for osteoporosis: State of the science","volume":"155","author":"Wysocki","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-123-1-199507010-00003","article-title":"Effect of starting age of physical activity on bone mass in the dominant arm of tennis and squash players","volume":"123","author":"Kannus","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1359\/jbmr.2003.18.2.352","article-title":"Effect of long-term impact-loading on mass, size, and estimated strength of humerus and radius of female racquet-sports players: A peripheral quantitative computed tomography study between young and old starters and controls","volume":"18","author":"Kontulainen","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","first-page":"3557","article-title":"Osteoporosis-risk factors, pharmaceutical and non-pharmaceutical treatment","volume":"25","author":"Kosiorowska","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhao, R., Xu, Z., and Zhao, M. (2015). Antiresorptive agents increase the effects of exercise on preventing postmenopausal bone loss in women: A meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116729"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clnesp.2017.06.001","article-title":"Malnutrition in the elderly and its effects on bone health\u2013A review","volume":"21","author":"Siddique","year":"2017","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clnu.2017.01.005","article-title":"Sufficient levels of 25-hydroxyvitamin D and protein intake required to increase muscle mass in sarcopenic older adults\u2013The PROVIDE study","volume":"37","author":"Verlaan","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ganapathy, A., and Nieves, J.W. (2020). Nutrition and Sarcopenia\u2014What Do We Know?. Nutrients, 12.","DOI":"10.3390\/nu12061755"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2016). Dietary reference values for vitamin D. EFSA J., 14, e04547.","DOI":"10.2903\/j.efsa.2016.4547"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsbmb.2015.01.023","article-title":"Vitamin D: Dietary requirements and food fortification as a means of helping achieve adequate vitamin D status","volume":"148","author":"Cashman","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","article-title":"Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis","volume":"370","author":"Tang","year":"2007","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jamda.2017.05.026","article-title":"Minerals and Sarcopenia; The Role of Calcium, Iron, Magnesium, Phosphorus, Potassium, Selenium, Sodium, and Zinc on Muscle Mass, Muscle Strength, and Physical Performance in Older Adults: A Systematic Review","volume":"19","author":"Abdelrazek","year":"2018","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.csbj.2019.07.005","article-title":"High Versus low Dietary Protein Intake and Bone Health in Older Adults: A Systematic Review and Meta-Analysis","volume":"17","author":"Groenendijk","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3945\/ajcn.116.145110","article-title":"Dietary protein and bone health: A systematic review and meta-analysis from the National Osteoporosis Foundation","volume":"105","author":"Chung","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0029665120007909","article-title":"Dietary protein and bone health: Towards a synthesised view","volume":"80","author":"Darling","year":"2021","journal-title":"Proc. Nutr. Soc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group","volume":"14","author":"Bauer","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_69","first-page":"929","article-title":"Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group","volume":"33","author":"Deutz","year":"2014","journal-title":"Clin. Nutr. Edinb. Scotl."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2020.12.009","article-title":"Exercise, Nutrition, and Combined Exercise and Nutrition in Older Adults with Sarcopenia: A Systematic Review and Network Meta-analysis","volume":"145","author":"Wu","year":"2021","journal-title":"Maturitas"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/TCRM.S54772","article-title":"Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates","volume":"10","author":"Iwamoto","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","article-title":"Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)","volume":"27","author":"Ringe","year":"2007","journal-title":"Rheumatol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00774-015-0695-x","article-title":"Eldecalcitol improves muscle strength and dynamic balance in postmenopausal women with osteoporosis: An open-label randomized controlled study","volume":"34","author":"Saito","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ecl.2024.08.001","article-title":"An Update on the Fracture Risk Assessment Tool: What Have We Learned over 15+ years?","volume":"53","author":"Dickens","year":"2024","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"AMG 162 Bone Loss Study Group Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Khosla","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_80","first-page":"S80","article-title":"A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: Results from the FREEDOM trial","volume":"23","author":"Cummings","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Chen, Y., Zhu, J., Zhou, Y., Peng, J., and Wang, B. (2021). Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.588095"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1111\/jgs.16165","article-title":"Effect of Denosumab on Falls, Muscle Strength, and Function in Community-Dwelling Older Adults","volume":"67","author":"Phu","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00198-022-06470-3","article-title":"Beneficial effects of denosumab on muscle performance in patients with low BMD: A retrospective, propensity score-matched study","volume":"33","author":"Rupp","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"117552","DOI":"10.1016\/j.bone.2025.117552","article-title":"Impact of denosumab on muscle health in older adults in long-term care","volume":"198","author":"Haeri","year":"2025","journal-title":"Bone"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: Anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1007\/s10067-021-05757-w","article-title":"Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?","volume":"40","author":"Miedany","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11657-024-01475-3","article-title":"Catholic Medical Center Bone Research Group Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass","volume":"20","author":"Ha","year":"2025","journal-title":"Arch. Osteoporos."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1097\/MJT.0000000000000415","article-title":"Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials","volume":"24","author":"Wang","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_93","first-page":"CD004523","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"5","author":"Wells","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_94","first-page":"78","article-title":"Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies","volume":"29","author":"Mendes","year":"2023","journal-title":"JCR J. Clin. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jcsm.12289","article-title":"Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation","volume":"9","author":"Chiu","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.bbrc.2016.10.112","article-title":"Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy","volume":"480","author":"Watanabe","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"116245","DOI":"10.1016\/j.bone.2021.116245","article-title":"Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition","volume":"154","author":"Trivedi","year":"2022","journal-title":"Bone"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jbmr.3890","article-title":"Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy","volume":"35","author":"Hain","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00774-017-0891-y","article-title":"Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women","volume":"36","author":"Urano","year":"2018","journal-title":"J. Bone Miner. Metab."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Pin, F., Bonetto, A., Bonewald, L.F., and Klein, G.L. (2019). Molecular Mechanisms Responsible for the Rescue Effects of Pamidronate on Muscle Atrophy in Pediatric Burn Patients. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00543"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2147\/DDDT.S328858","article-title":"Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients","volume":"15","author":"Huang","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00774-020-01118-w","article-title":"Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis","volume":"38","author":"Suzuki","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/GME.0b013e31827cabca","article-title":"Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women","volume":"20","author":"Park","year":"2013","journal-title":"Menopause"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.afos.2015.07.005","article-title":"Effect of alendronate on muscle mass: Investigation in patients with osteoporosis","volume":"1","author":"Harada","year":"2015","journal-title":"Osteoporos. Sarcopenia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bone.2015.02.018","article-title":"The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations","volume":"75","author":"Uchiyama","year":"2015","journal-title":"Bone"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.archger.2017.01.017","article-title":"Association between bisphosphonate therapy and outcomes from rehabilitation in older people","volume":"70","author":"Goodbrand","year":"2017","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"h3783","DOI":"10.1136\/bmj.h3783","article-title":"Bisphosphonates for the prevention and treatment of osteoporosis","volume":"351","author":"Maraka","year":"2015","journal-title":"BMJ"},{"key":"ref_108","unstructured":"The U.S. Food and Drug Administration (FDA) (2019). FDA Drug Safety Communication: Safety Update for Osteoporosis Drugs, Bisphosphonates, and Atypical Fractures, The U.S. Food and Drug Administration (FDA)."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Kawada, S., Harada, A., and Hashimoto, N. (2017). Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181457"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jphp.12171","article-title":"Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells","volume":"66","author":"Shiomi","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S8756-3282(03)00082-6","article-title":"Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial","volume":"33","author":"Kannus","year":"2003","journal-title":"Bone"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/os.12701","article-title":"Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80\u2009Years of Age and Older: A Randomized Controlled Study","volume":"12","author":"Zhou","year":"2020","journal-title":"Orthop. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/rco2.59","article-title":"Risedronate or exercise for lean mass preservation during menopause: Secondary analysis of a randomized controlled trial","volume":"5","author":"Flores","year":"2022","journal-title":"JCSM Rapid Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00198-021-06083-2","article-title":"Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: A randomized controlled trial","volume":"33","author":"Waltman","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.14283\/jfa.2022.54","article-title":"Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial","volume":"11","author":"Haeri","year":"2022","journal-title":"J. Frailty Aging"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00223-019-00653-7","article-title":"Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial","volume":"106","author":"Reid","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpeds.2005.10.041","article-title":"Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta","volume":"148","author":"Land","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1210\/jc.2006-0173","article-title":"Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men","volume":"91","author":"Fink","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study","volume":"87","author":"Feldman","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women\u2019s Health Initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/13697137.2013.795683","article-title":"Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health","volume":"16","author":"Pines","year":"2013","journal-title":"Climacteric J. Int. Menopause Soc."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Riggs","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_128","first-page":"37","article-title":"Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women","volume":"81","author":"Raisz","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199707103370204","article-title":"Effect of testosterone and estradiol in a man with aromatase deficiency","volume":"337","author":"Carani","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.bone.2007.01.022","article-title":"Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: Evidences of a priming effect of estrogen for sex steroids action on bone","volume":"40","author":"Rochira","year":"2007","journal-title":"Bone"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199808273390905","article-title":"Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency","volume":"339","author":"Bilezikian","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/eje.0.1400271","article-title":"Androgen effects on bone metabolism: Recent progress and controversies","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Eur. J. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.maturitas.2019.07.001","article-title":"Global Consensus Position Statement on the use of Testosterone Therapy for Women","volume":"128","author":"Davis","year":"2019","journal-title":"Maturitas"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone Therapy in Men with Hypogonadism: An Endocrine Society* Clinical Practice Guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Kang, D., and Li, H. (2020). The effects of testosterone on bone health in males with testosterone deficiency: A systematic review and meta-analysis. BMC Endocr. Disord., 20.","DOI":"10.1186\/s12902-020-0509-6"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40618-021-01702-5","article-title":"Testosterone supplementation and bone parameters: A systematic review and meta-analysis study","volume":"45","author":"Corona","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/1381612825666190206223244","article-title":"Testosterone Replacement Therapy Has Limited Effect on Increasing Bone Mass Density in Older Men: A Meta-analysis","volume":"25","author":"Junjie","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eprac.2023.04.013","article-title":"Safety and Efficacy of Testosterone Therapy on Musculoskeletal Health and Clinical Outcomes in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"29","author":"Buratto","year":"2023","journal-title":"Endocr. Pract."},{"key":"ref_139","first-page":"1966","article-title":"Effect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age1","volume":"84","author":"Snyder","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/jc.2003-031110","article-title":"Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone","volume":"89","author":"Amory","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/13685538.2013.773420","article-title":"Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: A 1-year, randomized, placebo-controlled, dose-ranging study","volume":"16","author":"Bouloux","year":"2013","journal-title":"Aging Male"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Deepika, F., Ballato, E., Colleluori, G., Aguirre, L., Chen, R., Qualls, C., Villareal, D.T., and Armamento-Villareal, R. (2022). Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.915309"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/13685530802273715","article-title":"Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men","volume":"11","author":"Basurto","year":"2008","journal-title":"Aging Male"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1210\/en.2003-1016","article-title":"Targeted overexpression of androgen receptor in osteoblasts: Unexpected complex bone phenotype in growing animals","volume":"145","author":"Wiren","year":"2004","journal-title":"Endocrinology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bone.2008.04.026","article-title":"Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis A model for compartment-specific androgen action in the skeleton","volume":"43","author":"Wiren","year":"2008","journal-title":"Bone"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/jc.2009-0739","article-title":"Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels","volume":"94","author":"McKay","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1359\/jbmr.090208","article-title":"Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects","volume":"24","author":"Lagerquist","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00018-011-0883-3","article-title":"Androgens and skeletal muscle: Cellular and molecular action mechanisms underlying the anabolic actions","volume":"69","author":"Dubois","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"111106","DOI":"10.1016\/j.exger.2020.111106","article-title":"Effect of testosterone supplementation on sarcopenic components in middle-aged and elderly men: A systematic review and meta-analysis","volume":"142","author":"Parahiba","year":"2020","journal-title":"Exp. Gerontol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1532-5415.2010.02865.x","article-title":"Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty","volume":"58","author":"Kenny","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_151","first-page":"9742","article-title":"Effects of testosterone on lean mass gain in elderly men: Systematic review with meta-analysis of controlled and randomized studies","volume":"37","author":"Neto","year":"2015","journal-title":"Age Dordr. Neth."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jcsm.12291","article-title":"Muscular responses to testosterone replacement vary by administration route: A systematic review and meta-analysis","volume":"9","author":"Skinner","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1159\/000532062","article-title":"Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis","volume":"69","author":"Lee","year":"2023","journal-title":"Gerontology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1210\/jc.2004-1933","article-title":"Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T","volume":"90","author":"Page","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2174\/1381612827666211115155541","article-title":"Testosterone Supplementation on Sarcopenia Components in Chronic Patients: A Systematic Review and Meta-Analysis","volume":"28","author":"Correa","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1532-5415.2008.01927.x","article-title":"Changes in Muscle Mass, Muscle Strength and Power, but not Physical Function are Related to Testosterone Dose in Healthy Older Men","volume":"56","author":"Storer","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11154-021-09634-4","article-title":"Can conditions of skeletal muscle loss be improved by combining exercise with anabolic-androgenic steroids? A systematic review and meta-analysis of testosterone-based interventions","volume":"22","author":"Falqueto","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-8587(18)30171-2","article-title":"The Effects of Testosterone Replacement on Self-reported and Performance-based Measures of Mobility in Older Men with Mobility Limitation and Low Testosterone Levels: A Placebo-Controlled Trial","volume":"6","author":"Bhasin","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1530\/eje.1.02291","article-title":"Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men","volume":"155","author":"Katznelson","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Endocrine Society Osteoporosis in men: An Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 Hormone Therapy Position Statement of The North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"ref_163","first-page":"380","article-title":"The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis","volume":"16","author":"Abdi","year":"2017","journal-title":"Iran. J. Pharm. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/GME.0000000000000519","article-title":"Effect of hormone therapy on the risk of bone fractures: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Zhu","year":"2016","journal-title":"Menopause"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00418-008-0512-x","article-title":"Expression of both oestrogen receptor alpha and beta in human skeletal muscle tissue","volume":"131","author":"Wiik","year":"2009","journal-title":"Histochem. Cell Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.ejcn.1601198","article-title":"Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years","volume":"55","author":"Kyle","year":"2001","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jcsm.12547","article-title":"Muscle and bone mass in middle-aged women: Role of menopausal status and physical activity","volume":"11","author":"Aukee","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"E1306","DOI":"10.1210\/jc.2013-4470","article-title":"Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women","volume":"99","author":"Smith","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/gerona\/62.12.1407","article-title":"Proteolytic Gene Expression Differs at Rest and After Resistance Exercise Between Young and Old Women","volume":"62","author":"Raue","year":"2007","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1249\/MSS.0b013e3182496a41","article-title":"Muscle protein synthesis response to exercise training in obese, older men and women","volume":"44","author":"Smith","year":"2012","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/gerona\/glp082","article-title":"Hormone therapy and skeletal muscle strength: A meta-analysis","volume":"64","author":"Greising","year":"2009","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e1910154","DOI":"10.1001\/jamanetworkopen.2019.10154","article-title":"Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis","volume":"2","author":"Javed","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/gme.0b013e3181e3aab1","article-title":"Effect of hormone therapy on lean body mass, falls, and fractures: Six-year results from the Women\u2019s Health Initiative Hormone Trials","volume":"18","author":"Bea","year":"2011","journal-title":"Menopause"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/ajcn\/82.3.651","article-title":"Postmenopausal hormone therapy and body composition\u2014A substudy of the estrogen plus progestin trial of the Women\u2019s Health Initiative","volume":"82","author":"Chen","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1475-097X.2005.00628.x","article-title":"The effect of hormone replacement therapy and\/or exercise on skeletal muscle attenuation in postmenopausal women: A yearlong intervention","volume":"25","author":"Taaffe","year":"2005","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1152\/japplphysiol.91518.2008","article-title":"Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: A study with monozygotic twin pairs","volume":"107","author":"Ronkainen","year":"2009","journal-title":"J. Appl. Physiol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1249\/01.mss.0000181678.28092.31","article-title":"Estrogen replacement, muscle composition, and physical function: The Health ABC Study","volume":"37","author":"Taaffe","year":"2005","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_179","first-page":"147","article-title":"Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: A randomized placebo-controlled study","volume":"101","author":"Taaffe","year":"2001","journal-title":"Clin. Sci. 1979"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"M436","DOI":"10.1093\/gerona\/58.5.M436","article-title":"Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy","volume":"58","author":"Kenny","year":"2003","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women\u2019s Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.289.20.2673","article-title":"Effect of estrogen plus progestin on stroke in postmenopausal women: The Women\u2019s Health Initiative: A randomized trial","volume":"289","author":"Hendrix","year":"2003","journal-title":"JAMA"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2013.10.009","article-title":"The Women\u2019s Health Initiative trial and related studies: 10 years later: A clinician\u2019s view","volume":"142","author":"Gurney","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.GME.0000086467.82759.DA","article-title":"Recency and duration of postmenopausal hormone therapy: Effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study","volume":"10","author":"Wehren","year":"2003","journal-title":"Menopause"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0002-9343(99)80251-4","article-title":"The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women","volume":"99","author":"Grey","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e2243951","DOI":"10.1001\/jamanetworkopen.2022.43951","article-title":"Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women with Breast Cancer","volume":"5","author":"Ryu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1345\/aph.1P604","article-title":"Lasofoxifene: Selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis","volume":"45","author":"Peterson","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13697137.2017.1289659","article-title":"The quest for new drugs to prevent osteoporosis-related fractures","volume":"20","year":"2017","journal-title":"Climacteric J. Int. Menopause Soc."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1185\/030079905X75032","article-title":"The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: A secondary analysis of the MORE trial","volume":"21","author":"Qu","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09513590701414907","article-title":"Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis","volume":"23","author":"Dane","year":"2007","journal-title":"Gynecol. Endocrinol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archinte.164.8.871","article-title":"A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women","volume":"164","author":"Reid","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2009.10.043","article-title":"The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women","volume":"46","author":"Naylor","year":"2010","journal-title":"Bone"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/GME.0000000000000419","article-title":"A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: Effects on bone density and fracture","volume":"22","author":"Palacios","year":"2015","journal-title":"Menopause"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Bazedoxifene Study Group Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jbmr.252","article-title":"Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis","volume":"26","author":"Itabashi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2019.1615882","article-title":"Bazedoxifene for the treatment of osteoporosis","volume":"20","author":"Yavropoulou","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"SMART-5 Investigators Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: A randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/GME.0000000000000694","article-title":"Effect of conjugated estrogens\/bazedoxifene on postmenopausal bone loss: Pooled analysis of two randomized trials","volume":"23","author":"Gallagher","year":"2016","journal-title":"Menopause"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climacteric J. Int. Menopause Soc."},{"key":"ref_212","first-page":"178","article-title":"Conjugated Estrogens\/Bazedoxifene (Duavee): A Novel Agent for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause and the Prevention of Postmenopausal Osteoporosis","volume":"40","author":"Goldberg","year":"2015","journal-title":"P T Peer-Rev. J. Formul. Manag."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/EJE-09-0619","article-title":"Raloxifene and body composition and muscle strength in postmenopausal women: A randomized, double-blind, placebo-controlled trial","volume":"162","author":"Jacobsen","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"189.e1","DOI":"10.1016\/j.jamda.2011.05.005","article-title":"Raloxifene and tibolone in elderly women: A randomized, double-blind, double-dummy, placebo-controlled trial","volume":"13","author":"Jacobsen","year":"2012","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.gme.0000227335.27996.d8","article-title":"Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene","volume":"13","author":"Tommaselli","year":"2006","journal-title":"Menopause"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1111\/bcp.13345","article-title":"The long and winding road for selective androgen receptor modulators","volume":"83","author":"Dalton","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"114119","DOI":"10.1016\/j.ejmech.2022.114119","article-title":"Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998\u20132021)","volume":"230","author":"Xie","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_219","unstructured":"Akel, M., and Parmar, M. (2023). Abaloparatide. StatPearls, StatPearls Publishing."},{"key":"ref_220","unstructured":"Vall, H., and Parmar, M. (2023). Teriparatide. StatPearls, StatPearls Publishing."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13018-023-03595-x","article-title":"Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis","volume":"18","author":"Hong","year":"2023","journal-title":"J. Orthop. Surg."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"e18964","DOI":"10.1097\/MD.0000000000018964","article-title":"Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients","volume":"99","author":"Fan","year":"2020","journal-title":"Medicine"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"PaTH Study Investigators One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Kontogeorgos, G., Krantz, E., Trimpou, P., Laine, C.M., and Landin-Wilhelmsen, K. (2022). Teriparatide treatment in severe osteoporosis-a controlled 10-year follow-up study. BMC Musculoskelet. Disord., 23.","DOI":"10.1186\/s12891-022-05987-2"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ki.1985.190","article-title":"Effect of parathyroid hormone on energy metabolism ofskeletal muscle","volume":"28","author":"Baczynski","year":"1985","journal-title":"Kidney Int."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1172\/JCI110936","article-title":"Effects of Parathyroid Hormone on Skeletal Muscle Protein and Amino Acid Metabolism in the Rat","volume":"71","author":"Garber","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2106\/JBJS.15.01217","article-title":"Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture","volume":"98","author":"Aspenberg","year":"2016","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jbmr.3067","article-title":"Effect of Teriparatide or Risedronate in Elderly Patients with a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial","volume":"32","author":"Tarantino","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","article-title":"Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women","volume":"93","author":"Peichl","year":"2011","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s11999-015-4669-z","article-title":"Does Teriparatide Improve Femoral Neck Fracture Healing: Results from a Randomized Placebo-controlled Trial","volume":"474","author":"Bhandari","year":"2016","journal-title":"Clin. Orthop."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Jepsen, D.B., Masud, T., Holsgaard-Larsen, A., Hansen, S., J\u00f8rgensen, N.R., and Ryg, J. (2020). The combined effect of parathyroid hormone (1\u201334) and whole-body vibration exercise on physical performance in OSteoporotic women (PaVOS study): A secondary analysis from a randomised controlled trial. BMC Sports Sci. Med. Rehabil., 12.","DOI":"10.1186\/s13102-020-00204-w"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","volume":"25","author":"Aspenberg","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00198-019-05029-z","article-title":"The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): A randomized controlled trial","volume":"30","author":"Jepsen","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/\u03b2-catenin signaling in bone","volume":"112","author":"Tu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update","volume":"105","author":"Shoback","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u20142020 Update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of Romosozumab Compared with Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women with Low Bone Mass","volume":"32","author":"Genant","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Magar\u00f2, M.S., Bertacchini, J., Florio, F., Zavatti, M., Pot\u00ec, F., Cavani, F., Amore, E., De Santis, I., Bevilacqua, A., and Reggiani Bonetti, L. (2021). Identification of Sclerostin as a Putative New Myokine Involved in the Muscle-to-Bone Crosstalk. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010071"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/bs.pmbts.2017.11.026","article-title":"Chapter Five\u2014Wnt Signaling in Skeletal Muscle Development and Regeneration","volume":"Volume 153","author":"Olivares","year":"2018","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s40610-017-0057-7","article-title":"Connecting Bone and Fat: The Potential Role for Sclerostin","volume":"3","author":"Fairfield","year":"2017","journal-title":"Curr. Mol. Biol. Rep."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3803\/EnM.2022.1428","article-title":"Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia","volume":"37","author":"Ahn","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"115053","DOI":"10.1016\/j.bone.2019.115053","article-title":"Association of serum sclerostin levels with low skeletal muscle mass: The Korean Sarcopenic Obesity Study (KSOS)","volume":"128","author":"Kim","year":"2019","journal-title":"Bone"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"4596920","DOI":"10.1155\/2020\/4596920","article-title":"Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes","volume":"2020","author":"Medeiros","year":"2020","journal-title":"Int. J. Nephrol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","article-title":"Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials","volume":"6","author":"Bartneck","year":"2020","journal-title":"Osteoporos. Sarcopenia"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.nmd.2023.07.381","article-title":"Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy","volume":"33","author":"Lair","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_256","unstructured":"Biohaven Ltd (2023). Biohaven\u2019s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy, Biohaven Ltd."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-physiol-012422-112116","article-title":"Myostatin: A Skeletal Muscle Chalone","volume":"85","author":"Lee","year":"2023","journal-title":"Annu. Rev. Physiol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1073\/pnas.1525795113","article-title":"Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice","volume":"113","author":"Camporez","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/gerona\/glad033","article-title":"Challenges and Future Prospects of Targeting Myostatin\/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction","volume":"78","author":"Lee","year":"2023","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.nmd.2016.06.037","article-title":"BMS-986089: A novel adnectin protein that dose dependently lowers free myostatin and increases muscle volume and lean body mass","volume":"26","author":"Jacobsen","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Wagner, K.R., Wong, B.L., Byrne, B.J., Tian, C., Jacobsen, L.K., Tirucherai, G.S., Rabbia, M., Kletzl, H., Dukart, J., and Ong, R. (2019). A Phase 1b\/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062). Neurology, 92.","DOI":"10.1212\/WNL.92.15_supplement.P1.6-062"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study","volume":"65","author":"Rooks","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"e2020836","DOI":"10.1001\/jamanetworkopen.2020.20836","article-title":"Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults","volume":"3","author":"Rooks","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(21)00084-2","article-title":"Bimagrumab to improve recovery after hip fracture in older adults: A multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a\/b trial","volume":"2","author":"Hofbauer","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/jcsm.12639","article-title":"Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort","volume":"11","author":"Rooks","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_267","first-page":"62","article-title":"A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty","volume":"5","author":"Woodhouse","year":"2016","journal-title":"J. Frailty Aging"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.nmd.2020.05.002","article-title":"Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy","volume":"30","author":"Wagner","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/mus.26113","article-title":"Locally acting ACE-083 increases muscle volume in healthy volunteers","volume":"57","author":"Glasser","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.27558","article-title":"Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy","volume":"66","author":"Statland","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_272","first-page":"56","article-title":"Myostatin (GDF-8) as a key factor linking muscle mass and bone structure","volume":"10","author":"Elkasrawy","year":"2010","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/biof.1675","article-title":"Molecular basis and therapeutic potential of myostatin on bone formation and metabolism in orthopedic disease","volume":"49","author":"Cui","year":"2023","journal-title":"BioFactors"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1474-9726.2009.00508.x","article-title":"Effects of Myostatin Deletion in Aging Mice","volume":"8","author":"Morissette","year":"2009","journal-title":"Aging Cell"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"13809","DOI":"10.1074\/jbc.M117.782128","article-title":"Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass","volume":"292","author":"Goh","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"14042","DOI":"10.1038\/boneres.2014.42","article-title":"Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta","volume":"3","author":"DiGirolamo","year":"2015","journal-title":"Bone Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1073\/pnas.0711263105","article-title":"A soluble activin type IIA receptor induces bone formation and improves skeletal integrity","volume":"105","author":"Pearsall","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2013.12.002","article-title":"A myostatin and activin decoy receptor enhances bone formation in mice","volume":"60","author":"Bialek","year":"2014","journal-title":"Bone"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1073\/pnas.1916034117","article-title":"GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN\/GDF11 inhibitor, increases muscle mass but weakens bone","volume":"117","author":"Suh","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6924\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:18Z","timestamp":1760033538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/14\/6924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":281,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26146924"],"URL":"https:\/\/doi.org\/10.3390\/ijms26146924","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}